<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>21839993</identifier>
<setSpec>1578-1860</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Moreno, V</dc:author>
<dc:author>Valencia, M E</dc:author>
<dc:description xml:lang="en">A 48-year old male coinfected by human immunodeficiency virus and hepatitis C virus (HCV) genotype 3a. The patient was under clinically and virologically effective treatment with Trizivir (zidovudine, lamivudine and abacavir) when it was decided to initiate treatment for the chronic HCV infection with peginterferon and ribavirin. Should the ongoing antiretroviral treatment be adjusted?</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2012 Jan </dc:date>
<dc:title xml:lang="es">Coinfección por VIH y VHC: abacavir y ribavirina, ¿por qué no?</dc:title>
<dc:title xml:lang="en">[Coinfection with HIV and HCV: abacavir and ribavirine, why not?].</dc:title>
<dc:publisher>Revista clinica espanola</dc:publisher>
</metadata>
</record>
</pubmed-document>
